key: cord-0738880-5zx43orf authors: Marx, Grace E; Biggerstaff, Brad J; Nawrocki, Courtney C; Totten, Sarah E; Travanty, Emily A; Burakoff, Alexis W; Scott, Tracy; De Hey, Jesse Chavez-Van; Carlson, Jesse J; Wendel, Karen A; Harcourt, Jennifer L; Tamin, Azaibi; Thomas, Jennifer D; Rowan, Sarah E title: SARS-CoV-2 detection on self-collected saliva or anterior nasal specimens compared with healthcare personnel-collected nasopharyngeal specimens date: 2021-04-29 journal: Clin Infect Dis DOI: 10.1093/cid/ciab330 sha: d00ff14c8c8cf9c0d28ca42edb8ef89730b79079 doc_id: 738880 cord_uid: 5zx43orf BACKGROUND: Nasopharyngeal specimens (NPS) are commonly used for SARS-CoV-2 testing but can be uncomfortable for patients. Self-collected saliva or anterior nasal specimens (ANS) for SARS-CoV-2 detection are less invasive but the sensitivity of these specimen types has not been thoroughly evaluated. METHODS: During September–November 2020, 730 adults undergoing SARS-CoV-2 testing at community testing events and homeless shelters in Denver provided self-collected saliva and ANS specimens before NPS collection and answered a short survey about symptoms and specimen preference. Specimens were tested for SARS-CoV-2 by rRT-PCR; viral culture was performed on a subset of specimens positive by rRT-PCR. Sensitivity of saliva and ANS for SARS-CoV-2 detection by rRT-PCR was measured against NPS. Subgroup analyses included test outcomes by symptom status and culture results. RESULTS: Sensitivity for SARS-CoV-2 detection by rRT-PCR appeared higher for saliva than for ANS (85% vs. 80%) and among symptomatic participants than among those without symptoms (94% vs. 29% for saliva; 87% vs. 50% for ANS). Among participants with culture-positive SARS-CoV-2 by any specimen type, sensitivity of saliva and ANS by rRT-PCR was 94% and 100%, respectively. Saliva and ANS were equally preferred by participants; most would undergo NPS again despite being least preferred. CONCLUSIONS: Saliva was slightly more sensitive than ANS for SARS-CoV-2 detection by rRT-PCR. Both saliva and ANS reliably detected SARS-CoV-2 among participants with symptoms. Self-collected saliva and ANS offer practical advantages, are preferred by patients, and might be most useful for testing people with COVID-19 symptoms. M a n u s c r i p t subset of paired NPS and ANS specimens from participants who tested positive for SARS-CoV-2 by rRT-PCR was sent for viral culture. This multilayered evaluation was designed to inform programmatic decisions about whether the less invasive specimens of saliva and ANS might be suitable alternatives to the traditional NPS for testing and screening programs in community and congregate living settings. We performed a cross-sectional evaluation of adults seeking SARS-CoV-2 testing at testing events held by Denver Public Health in Denver, Colorado during September-November 2020. Testing events took place at walk-up or drive-up sites in communities disproportionately affected by the pandemic and at shelters for people experiencing homelessness. We enrolled both symptomatic and asymptomatic participants. Participant inclusion criteria were (1) attending a SARS-CoV-2 testing event; (2) ≥18 years of age at date of testing; (3) able and willing to provide informed consent; and (4) willing to comply with study procedures. We excluded participants who reported receiving a previous positive SARS-CoV-2 test. This project was determined to be not human subject research by the Colorado Multiple Institutional Review Board (IRB) and by the Colorado Department of Public Health and Environment (CDPHE) IRB as a public health surveillance activity. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. § All participants provided verbal informed consent prior to enrollment. A c c e p t e d M a n u s c r i p t Trained healthcare personnel observed and coached participants to self-collect an ANS (inserting a polyester foam swab 1.0-1.5 cm and rotating it for 10-15 seconds in each nostril) and to provide a saliva specimen (1-5 mL) by spitting several times into a sterile container [3] . Healthcare personnel then collected NPS (mini-tip flocked polyester swab inserted through one naris to the nasopharynx and rotated for 5 seconds) [3] . ANS were immediately placed into a sterile transport tube containing 2-3 mL of sterile saline; NPS were immediately placed into a sterile transport tube containing 2-3 mL of viral transport medium (AccuViral Collection Kit TM ). All specimens were placed immediately in a cooler with ice packs. On the same day of collection, after each testing event, coolers were transported to the CDPHE laboratory and moved to 4:C refrigerators until processing within 72 hours of collection [3] . After specimen collection, trained interviewers asked structured survey questions from participants in English or Spanish. Questions included demographic characteristics, detailed assessment for COVID-19 symptoms, whether participants had close contact with a known case of COVID-19 in the past 2 weeks, which specimen type they preferred, and whether they would agree to be tested again by specimen type (Supplement Figure 1 ). COVID-19 symptoms in this investigation were defined as reports of new or worsening fever (measured or subjective) or chills, cough, shortness of breath or difficulty breathing, fatigue, myalgia, headache, anosmia or ageusia, sore throat, congestion or nasal discharge, nausea or vomiting, or diarrhea [10] . Data were entered into Research Electronic Data Capture (REDCap) software (Vanderbilt). M a n u s c r i p t All specimens were processed and tested for SARS-CoV-2 at the CDPHE laboratory using the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel assay protocol [1] . Nucleic acid extraction was performed according to the instructions for use authorized by the U.S. Food and Drug Administration for the assay. Saliva specimens were vortexed for one minute, then incubated at room temperature for 30 seconds before removing the slightly separated supernatant from a viscous bottom layer; nucleic acid extraction was performed on the supernatant. Results were considered positive for SARS-CoV-2 when cycle threshold (Ct) values for the viral nucleocapsid protein genes N1 and N2 were <40.00 [11] . Ct values from rRT-PCR tests are inversely correlated to the amount of viral genetic material present in the specimen [12] . A subset of paired ANS and NPS from participants who tested positive for SARS-CoV-2 by rRT-PCR by one or more specimen type was placed in cryovial boxes on ice packs and shipped to CDC for viral culture. Given limited viral culture testing capacity (maximum 100 specimens) and because of the practical challenges of processing saliva specimens for culture [13] , only ANS and NPS were submitted for viral culture. Specimens prioritized for this subset included 1) participants with discrepant results by rRT-PCR (e.g., a participant who tested positive by NPS but negative by ANS or saliva, or a participant who tested negative by NPS but positive by ANS or saliva) and 2) specimens with the lowest Ct values. These criteria were systematically applied until the allowed quantity of 100 specimens was identified. Viral culture was performed using Vero-CCL-81 cells as previously described [14] . rRT-PCR was performed on specimens that developed cytopathic effect to confirm isolation A c c e p t e d M a n u s c r i p t of infectious virus in culture. Recovery of infectious virus was confirmed if the Ct of the recovered isolate was at least 2 Ct lower than the clinical specimen [15] . Analyses were performed to evaluate and compare test performance of self-collected ANS and saliva specimens with NPS. Sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively), and likelihood ratios positive and negative (LRP and LRN, respectively), were computed for ANS and saliva using NPS as the reference standard; corresponding 95% score confidence intervals (CI) were calculated for each measure. Sensitivity and 95% CI of ANS or saliva for detection of SARS-CoV-2 by rRT-PCR were also computed, using culturable virus on any specimen as the reference standard. Not considering NPS as the reference standard, Cohen's kappa statistics (95% bootstrap CIs) were computed as measures of agreement between ANS and NPS, and between saliva and NPS. Pearson's correlations and 95% CI were calculated between rRT-PCR genetic targets N1 and N2 on ANS and NPS. Receiver-operating-characteristic (ROC) analysis of rRT-PCR Ct values was used to identify the cutoff Ct value which yielded maximum equal sensitivity and specificity. All statistical analyses were conducted using R software (version 4.0.2; Vienna, Austria). Of 730 total participants enrolled, 452 (61.9%) were enrolled at 10 community testing events and 278 (38.0%) at seven homeless shelter testing events. Age, gender, and race and ethnicity distributions differed among participants enrolled at community sites and homeless shelters (Table 1) . Participants enrolled at community sites tended to be younger (54.2% vs 30.6% aged ≤40 years) and more often female (57.3% vs 16.2%) compared to A c c e p t e d M a n u s c r i p t participants enrolled at homeless shelters. Hispanic ethnicity was more commonly reported by participants at community sites (44.0%) compared to participants at homeless shelters (20.9%); White, non-Hispanic race/ethnicity were more commonly reported by participants at homeless shelters (51.8%), compared to participants at community sites (39.2%). Overall, 36.8% of participants reported one or more symptom(s) consistent with COVID-19 [10] at the time of testing, with a much higher proportion of symptomatic participants enrolled at community sites (47.8%) than at homeless shelters (19.1%). Close contact with a person with confirmed COVID-19 was reported by 33.0% of participants at community sites compared to 3.6% of participants at homeless shelters. In total, 84 (11.5%) participants were positive for SARS-CoV-2 by rRT-PCR by at least one specimen type; 82 (97.6%) were enrolled at community sites. Saliva was the most preferred specimen type overall (45.9%), followed by ANS (37.3%), and NPS (13.4%). Specimen type preference did not differ by testing site type. The majority of participants from both sites indicated they would be willing to be tested again by ANS (98.5% at community sites and 93.2% at homeless shelters), saliva (98.2% at community sites and 94.6% at homeless shelters), and NPS (89.2% at community sites and 85.6% at homeless shelters) if each were the only specimen type being collected for testing. Conclusive (positive or negative) results were available for 544 saliva, 609 ANS, and 665 NPS specimens; 467 (64.0%) participants had conclusive results for all 3 specimen types ( Figure 1 ). Compared to NPS, overall sensitivity for detection of SARS-CoV-2 by rRT-PCR on saliva specimens was 85.2% (95% CI 73.4 -92.3%) and for ANS was 80.0% (95% CI 68.7 -87.9%) ( Table) . Using Cohen's kappa coefficient, agreement between saliva and NPS was 0.85 (95% CI 0.77 -0.93) and between ANS and NPS was 0.83 (0.76 -0.91). For all participants, Ct values for the N1 and N2 rRT-PCR targets were strongly correlated (r A c c e p t e d M a n u s c r i p t A total of 48 ANS and 51 NPS specimens from 51 participants were submitted for viral culture ( Figure 1 ); of these, conclusive (positive or negative) culture results were available for 50 NPS and 46 ANS from 50 participants (Table 3) . Culturable virus was detected in specimens from 19 (38%) participants, 6 in both NPS and ANS specimens, 12 in NPS only, and 1 in ANS only. Using culturable virus in any specimen type as the reference, sensitivity for SARS-CoV-2 detection by rRT-PCR was 100% (95% CI 83.2%-100%) for both NPS and ANS and 93.8% (95% CI 71.7%-99.7%) for saliva. In addition, among the 19 participants with culturable virus, one rRT-PCR result for saliva was inconclusive and one was invalid. Ct values for the N1 target were associated with overall culture result. ROC analysis showed that a Ct value of 18.7 was the optimal cutoff for detection of culturable SARS-CoV-2 (Supplement Figure 3) ; among specimens positive for SARS-CoV-2 by rRT-PCR, those with lower Ct values (<19) were more often positive by culture, while specimens with higher Ct values (≥19) were more often negative by culture ( Figure 2 ). In this investigation, most participants positive for SARS-CoV-2 by rRT-PCR on NPS also tested positive by self-collected saliva and ANS, especially participants reporting current symptoms. Agreement of results between specimen types (saliva and NPS; ANS and NPS) was high for participants reporting current symptoms. Adopting less invasive specimen collection could improve testing uptake, but the benefits of saliva and ANS for testing should be weighed carefully against the loss of sensitivity in asymptomatic people. A c c e p t e d M a n u s c r i p t These findings suggest that several strategies might be applied to optimize SARS-CoV-2 detection in self-collected saliva or ANS. When patients are unable or unwilling to undergo NPS collection, or when PPE or trained healthcare personnel are limited, self-collected saliva or ANS could be offered, acknowledging that some infections might be missed that would have been detected by NPS. Notably, most participants with discordant results between the three specimens had NPS Ct values >30, consistent with decreased genetic material in the sample and potentially nonviable virus, which is also consistent with prior studies [16] [17] [18] . Additionally, when evaluating the limited number of specimens that were tested for SARS-CoV-2 by viral culture and found to have culturable virus present, sensitivity by rRT-PCR of both saliva and ANS was high (94% and 100%, respectively), suggesting that the lower sensitivity of saliva and ANS may not be clinically relevant. Given the low sensitivity among asymptomatic individuals, self-collected saliva or ANS specimens are likely to be most useful to test people reporting current COVID-19 symptoms. Testing both saliva and ANS in parallel for individual participants appeared to increase sensitivity, but this strategy may be impractical given the increased burden on laboratory resources. Pooled saliva/ANS specimens could be a subject of future research. While saliva specimens had a modestly higher overall sensitivity than ANS for SARS-CoV-2 detection in this investigation, the sensitivity of saliva among asymptomatic participants was notably lower than among symptomatic participants and lower than has been previously reported [19] . Some participants were unable to produce saliva, while others were able to produce saliva but in volumes insufficient for testing ( Figure 1 ). Laboratory personnel reported that saliva was difficult to process and often required additional processing to yield valid results, consistent with prior reports [13, 20] . The usefulness of saliva as a specimen A c c e p t e d M a n u s c r i p t might be limited if participants are unable to produce adequate specimens or if the laboratory has limited resources to resolve saliva processing issues. One approach that has shown promise to standardize sampling of the oral cavity for SARS-CoV-2 testing is the saline mouth rinse/gargle method [21], which might overcome challenges when saliva production is limited. Because our study objective was to evaluate test performance during real-life testing events, we did not exclude participants who ate, drank, brushed their teeth, or smoked immediately prior to sampling, which might have affected test performance of This evaluation had several limitations. First, participants were enrolled in a single large urban area and might not be representative of other communities. Second, the changing dynamics of SARS-CoV-2 test-seeking behavior and SARS-CoV-2 incidence in Denver during the enrollment period [24, 25] limited ability to compare test performance by testing location type. Overall positivity rates in Denver during the period of study enrollment ranged from 2% in early September, 2020 to 12% in November, 2020. More specifically, at Denver Public Health testing events during this period, the positivity rates ranged from 2 -33% at community sites and 0 -8% in homeless shelters. In addition, survey responses were self-reported; therefore, responses might be subject to social desirability or recall biases. Finally, because only a nonrandom subset of samples was evaluated by viral culture, inferential statements based on the findings reported here should be evaluated in a separate study to ensure generalizability. A c c e p t e d M a n u s c r i p t Strengths of this analysis include its design using specimens collected from actual community events and inclusion of a diverse group of participants from events that frequently had relatively high positivity rates. The addition of symptom status, Ct values, and viral culture data to the qualitative rRT-PCR results supports a more complete understanding of the usefulness of ANS and saliva specimens to detect clinically meaningful SARS-CoV-2 infection. While use of self-collected saliva and ANS specimens offers practical advantages, challenges to collect and process saliva might be a limitation [13] . Understanding the benefits and limitations of less-invasive specimen collection procedures for SARS-CoV-2 testing should inform public health efforts to design testing programs most appropriate to the local context and population and could possibly improve test uptake. Development of SARS-CoV-2 testing programs should consider differences in test sensitivity by specimen type, logistical and practical factors of offering testing in different settings, and specimen preferences by those seeking testing. For high volume testing events, self-collected ANS specimens are a preferred alternative to more invasive NPS by patients, are easier to collect and process than saliva, and reliably detect SARS-CoV-2 among people who are symptomatic. US Department of Health and Human Services, CDC Clinical Samples for SARS-CoV-2 Detection: Review of the Early Literature Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19 Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic Accuracy and Discomfort of Different Types of Intranasal Specimen Collection Methods for Molecular Influenza Testing in Emergency Department Patients Testing: What SARS-CoV-2 testing services do adults in the United States actually want? A discrete choice experiment Saliva is a reliable tool to detect SARS-CoV-2 Detection of SARS-CoV-2 in Different Types of Clinical Specimens Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19 GA: US Department of Health and Human Services, CDC US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility Sensitive, Full-Genome Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2 Predicting infectious SARS-CoV-2 from diagnostic samples Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19 Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: A systematic review and metaanalysis Abbreviations: ANS, anterior nasal specimen LRN, likelihood ratio negative a Symptoms defined as new or worsening fever (subjective or objective) or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new anosmia or ageusia, sore throat, congestion or nasal discharge Analysis restricted to participants with conclusive positive or negative results on both anterior nasal specimens and nasopharyngeal specimens Analysis restricted to participants with conclusive positive or negative results on both saliva and nasopharyngeal specimens. d Agreement calculated using Cohen's kappa correlation coefficient Participants in Denver, Colorado; Sarah Stella, MD (Denver Health and A c c e p t e d M a n u s c r i p t